
BRUSSELS – The reduction to the lifetime of pharmaceutical patents has come one step closer to having a permanent place in European law.
On Wednesday, the EU Parliament approved the report that forms the basis of the strategy text with a significant majority, with 527 votes for the strategy out of a possible 689.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app